Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 812 of 5804
-
Engineered immune cells show promise against hard-to-treat leukemia
Disease control OngoingThis is a single-arm, open-label, single-center, phase I/II study to determine the safety and efficacy of CD19 CAR-T(ssCART-19) combined with autologous T cells engineered to express CD19, namely CD19+ feeding T cells (FTCs), as consolidation therapy in patients diagnosed with de…
Phase: PHASE1, PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Bladder cancer study aims to keep tumors at bay with immunotherapy
Disease control OngoingThis is a phase 2, single arm, open label trial to evaluate the rate of failure free survival at 2 years after start of chemoradiation with adjuvant nivolumab in adult subjects who undergo chemoradiation for localized bladder cancer.
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Proton therapy offers new hope for head and neck cancer that returns
Disease control CompletedThe purpose of this study is to evaluate the tumor control and the side effects of using proton therapy for head and neck cancer that has come back.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for Hard-to-Treat breast cancer? alisertib combo tested
Disease control CompletedThis phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell g…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug aims to help boys with duchenne walk longer
Disease control CompletedThis study is a long-term study of ataluren in participants with nonsense mutation Duchenne muscular dystrophy.
Phase: PHASE3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for pancreatic cancer? immunotherapy cocktails tested in major trial
Disease control CompletedA Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Two c…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New imaging technique could improve stent outcomes in heart patients
Disease control OngoingThe purpose is to compare median two-year clinical outcome after OCT guided vs. standard guided revascularization of patients requiring complex bifurcation stent implantation
Phase: NA • Sponsor: Aarhus University Hospital Skejby • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for kids with sickle cell: stem cell transplant from mismatched blood type donors
Disease control Recruiting nowThe aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with sickle cell disease (SCD) who have a matched related major ABO-incompatible donor. The non…
Phase: PHASE2 • Sponsor: University of Calgary • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New transplant approach shows promise for rare blood disorder
Disease control CompletedThis study is a prospective, multicenter phase II study with patients receiving haploidentical transplantation for Severe Aplastic Anemia (SAA). The primary objective is to assess overall survival (OS) at 1 year post-hematopoietic stem cell transplantation (HSCT).
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Ketamine during breast cancer surgery may stop chronic pain before it starts
Prevention CompletedAim 1: To determine the effectiveness of perioperatively administered ketamine to decrease acute and persistent postmastectomy pain (PPMP). Hypothesis 1.1: Patients undergoing partial or total mastectomy treated with a bolus and perioperative infusion of the NMDA-receptor antago…
Phase: EARLY_PHASE1 • Sponsor: Brigham and Women's Hospital • Aim: Prevention
Last updated Jul 22, 2026 00:00 UTC
-
New cocktail aims to keep myeloma at bay longer
Disease control OngoingThis study will assess whether adding one of the newest multiple myeloma therapies, daratumumab, into the Total Therapy approach helps patients live longer with fewer side effects
Phase: PHASE2 • Sponsor: University of Arkansas • Aim: Disease control
Last updated Jun 26, 2026 15:40 UTC
-
Microbubble 'Pops' could supercharge liver cancer radiation
Disease control CompletedThis phase II trial studies how well perflutren protein-type A microspheres and contrast-enhanced ultrasound work in improving response to radioembolization therapy in patients with liver cancer. Ultrasound contrast agents, such as perflutren protein-type A microspheres, use gas …
Phase: PHASE2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New combo therapy targets Hard-to-Treat liver and stomach cancers
Disease control Recruiting nowThis is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, adv…
Phase: PHASE2 • Sponsor: Teclison Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Could a sleep apnea machine keep heart patients out of the hospital?
Disease control TerminatedThe purpose of this study is to determine whether early diagnosis of obstructive sleep apnea and initiation of and adherence to CPAP therapy in hospitalized cardiac patients would impact 30-day hospital readmission rates.
Phase: NA • Sponsor: Kaiser Permanente • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Head-to-Head trial tests biologics to save sight in stubborn uveitis
Disease control CompletedRUBI, is the first prospective randomized, head to head study, comparing Adalimumab to either anakinra, or tocilizumab in refractory Non Infectious Uveitis (NIU). There is no firm evidence or randomized controlled trials directly addressing the best biologic agent in severe and r…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 26, 2026 17:50 UTC
-
Could a bone marrow shield improve chemo for aggressive lung cancer?
Disease control CompletedThis was a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing antitumor efficacy when administered with carboplatin, etoposide, and atezolizumab (E/P/A) therapy in first line treatment for …
Phase: PHASE2 • Sponsor: G1 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Radiation boost may help immunotherapy fight lung cancer
Disease control CompletedThis phase II trial studies how well radical-dose image guided radiation therapy works in treating patients with non-small cell lung cancer that has spread to other places in the body who are undergoing immunotherapy. Radiation therapy uses high energy x-rays to kill tumor cells …
Phase: NA • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo shows promise for tough leukemia cases
Disease control CompletedThis phase II trial studies how well ibrutinib and blinatumomab work in treating patients with B acute lymphoblastic leukemia that has come back or is not responding to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth…
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New catheter device offers hope for leaky heart valve patients
Disease control CompletedThe purpose of this study is to assess the safety, performance and clinical outcomes of the Edwards PASCAL Transcatheter Mitral Valve Repair (TMVr) System.
Phase: NA • Sponsor: Edwards Lifesciences • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Could an antibody slow Parkinson's? new trial hopes to find out
Disease control OngoingThis multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxi…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC